Irbesartan/Hydrochloorthiazide Focus (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors, preventing the hormone from causing blood vessels to narrow and from stimulating aldosterone release. This leads to vasodilation and reduced sodium‑water retention, helping to lower blood pressure.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety in pregnancy and lactation has not been fully established. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

This combination offers dual action—angiotensin II blockade and diuretic‑induced volume reduction—in a single tablet, which can simplify regimens compared with taking separate ARB and thiazide agents. It is often chosen when monotherapy does not achieve target blood pressure.

Store the tablets at ambient temperature, below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight, and excessive heat to maintain product stability.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe hypotension, acute kidney injury, marked electrolyte disturbances such as hyper‑ or hypokalemia, and rare cases of angioedema. Patients should seek immediate medical attention if they experience swelling of the face, lips, tongue, or difficulty breathing.

Individuals with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation should avoid this product. It is also contraindicated in patients with severe renal impairment, anuria, or those who are pregnant unless the benefits outweigh the risks.